sellWeak10b5-1 plan
Anand Sampath sold $2.6M of MASI
EVP, Ops & Clinical Research at MASIMO CORP. 18,680 shares at an average of $136.81, traded Jan 28, 2026, filed Jan 30, 2026.
Warning score
15Value
$2.6M
18,680 shares
Holdings after
40,909
-31% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +25Trade size$2.6M at market
- +10Share of holdings soldSold 31% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000937556-26-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 28, 2026 | MOption exercise Common Stock | +30,000 | $37.84 | $1.1M | 59,589 | Jan 30, 2026 |
| Jan 28, 2026 | SOpen-market sale Common Stock10b5-1 | -11,924 | $136.56 | $1.6M | 47,665 | Jan 30, 2026 |
| Jan 28, 2026 | SOpen-market sale Common Stock10b5-1 | -6,560 | $137.22 | $900k | 41,105 | Jan 30, 2026 |
| Jan 28, 2026 | SOpen-market sale Common Stock10b5-1 | -196 | $138.09 | $27k | 40,909 | Jan 30, 2026 |
| Jan 28, 2026 | MOption exercise Non-Qualified Stock Option (Right to Buy)derivative | -30,000 | $0.00 | $0 | 0 | Jan 30, 2026 |
Related signals
Other insiders at MASIMO CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | MASIMO CORP | Michelle Brennan Interim CEO | $31k 200 shares | +3% | |
| 50Moderate | MASIMO CORP | William R Jellison director | $438k 3,000 shares | +168% | |
| 20Weak | MASIMO CORP | Bilal Muhsin Chief Operating Officer | $1.6M 10,000 shares | -29% | |
| 25Weak | MASIMO CORP | Craig B Reynolds director | $5.4M 40,000 shares | -84% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.